ONCOCYTE CORPORATION

(OCX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Needham Lowers OncoCyte's Price Target to $5 From $7, Maintains Buy Rating

12/15/2021 | 02:58pm EDT


© MT Newswires 2021
All news about ONCOCYTE CORPORATION
05/16Piper Sandler Trims OncoCyte's Price Target to $1.40 From $1.80, Maintains Overweight R..
MT
05/12ONCOCYTE CORP Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/12Needham Adjusts OncoCyte's Price Target to $2.25 From $4 on 'Peer Multiple Compression,..
MT
05/11ONCOCYTE : Q1 Earnings Snapshot
AQ
05/11TRANSCRIPT : OncoCyte Corporation, Q1 2022 Earnings Call, May 11, 2022
CI
05/11ONCOCYTE CORP : Results of Operations and Financial Condition, Change in Directors or Prin..
AQ
05/11OncoCyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 202..
CI
05/11Oncocyte Reports First Quarter 2022 Financial Results
AQ
05/11Earnings Flash (OCX) ONCOCYTE CORPORATION Posts Q1 Revenue $1.4M
MT
05/05Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test
AQ
More news
Analyst Recommendations on ONCOCYTE CORPORATION
More recommendations
Financials (USD)
Sales 2022 9,48 M - -
Net income 2022 -50,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,39x
Yield 2022 -
Capitalization 144 M 144 M -
Capi. / Sales 2022 15,2x
Capi. / Sales 2023 6,71x
Nbr of Employees 113
Free-Float 91,9%
Chart ONCOCYTE CORPORATION
Duration : Period :
OncoCyte Corporation Technical Analysis Chart | OCX | US68235C1071 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,17 $
Average target price 4,06 $
Spread / Average Target 247%
EPS Revisions
Managers and Directors
Ronald Asbury Andrews President, Chief Executive Officer & Director
Mitchell Stuart Levine Chief Financial Officer
Andrew Arno Chairman
Douglas T. Ross Chief Science Officer
Ekkehard Schütz Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCOCYTE CORPORATION-46.08%144
GILEAD SCIENCES, INC.-12.99%79 248
REGENERON PHARMACEUTICALS, INC.5.71%71 927
VERTEX PHARMACEUTICALS19.24%66 967
WUXI APPTEC CO., LTD.-16.20%42 682
BIONTECH SE-38.01%38 834